Publications by authors named "V Enouf"
BackgroundEarly detection and characterisation of SARS-CoV-2 variants have been and continue to be essential for assessing their public health impact. In August 2023, Santé publique France implemented enhanced surveillance for BA.2.
View Article and Find Full Text PDFArticle Synopsis
- - First-generation monoclonal antibodies (mAbs) for COVID-19 were withdrawn due to resistance from Omicron variants, but two new mAbs, VYD222/Pemivibart and AZD3152/Sipavibart, were approved in 2024.
- - Researchers tested these mAbs against contemporary JN.1 sublineages and found VYD222 still had moderate activity, but AZD3152 lost effectiveness against several variants.
- - The study underscores the importance of monitoring VYD222's clinical performance and raises concerns about AZD3152's efficacy in treating infections from newer variants.
Background: Pacific Islanders are underrepresented in vaccine efficacy trials. Few studies describe their immune response to COVID-19 vaccination. Yet, this characterization is crucial to re-enforce vaccination strategies adapted to Pacific Islanders singularities.
View Article and Find Full Text PDFArticle Synopsis
- Respiratory syncytial virus (RSV) is a significant cause of hospitalizations and fatalities in infants globally, prompting France to start a national program administering nirsevimab, a monoclonal antibody treatment, to protect infants from RSV infections.
- A modeling study was conducted to evaluate the effectiveness of nirsevimab and estimate the number of RSV-related hospitalizations avoided in infants under 24 months during the 2023-24 season in France.
- The findings indicated that nirsevimab prevented approximately 5,800 RSV-associated hospitalizations for bronchiolitis in children under 24 months, with around 4,200 of these cases in infants aged 0-2 months.
Importance: In the context of emerging SARS-CoV-2 variants or lineages and new vaccines, it is key to accurately monitor COVID-19 vaccine effectiveness (CVE) to inform vaccination campaigns.
Objective: To estimate the effectiveness of COVID-19 vaccines administered in autumn and winter 2022 to 2023 against symptomatic SARS-CoV-2 infection (with all circulating viruses and XBB lineage in particular) among people aged 60 years or older in Europe, and to compare different CVE approaches across the exposed and reference groups used.
Design, Setting, And Participants: This case-control study obtained data from VEBIS (Vaccine Effectiveness, Burden and Impact Studies), a multicenter study that collects COVID-19 and influenza data from 11 European sites: Croatia; France; Germany; Hungary; Ireland; Portugal; the Netherlands; Romania; Spain, national; Spain, Navarre region; and Sweden.